2011
Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity
Fu S, Naing A, Moulder SL, Culotta KS, Madoff DC, Ng CS, Madden TL, Falchook GS, Hong DS, Kurzrock R. Phase I Trial of Hepatic Arterial Infusion of Nanoparticle Albumin–Bound Paclitaxel: Toxicity, Pharmacokinetics, and Activity. Molecular Cancer Therapeutics 2011, 10: 1300-1307. PMID: 21571911, DOI: 10.1158/1535-7163.mct-11-0259.Peer-Reviewed Original ResearchConceptsHepatic arterial infusionNab-paclitaxelHepatic extractionArterial infusionDose levelsNanoparticle Albumin-Bound PaclitaxelFirst-pass hepatic extractionPredominant liver metastasesCommon adverse eventsAdvanced cancer patientsAlbumin-Bound PaclitaxelDose-limiting toxicityPeak concentrationHighest dose levelStable diseaseAdverse eventsLiver involvementLiver metastasesPartial responseI trialComparative pharmacokinetic studyHepatic metastasesPoor outcomeCancer patientsNanoparticle albumin
2010
A phase I study of hepatic arterial infusion of nab-paclitaxel in patients with predominant hepatic metastases.
Fu S, Naing A, Moulder S, Falchook G, Culotta K, Zhang Y, Madoff D, Ng C, Lim J, Kurzrock R. A phase I study of hepatic arterial infusion of nab-paclitaxel in patients with predominant hepatic metastases. Journal Of Clinical Oncology 2010, 28: e13044-e13044. DOI: 10.1200/jco.2010.28.15_suppl.e13044.Peer-Reviewed Original Research